JP2023552554A5 - - Google Patents

Info

Publication number
JP2023552554A5
JP2023552554A5 JP2023534111A JP2023534111A JP2023552554A5 JP 2023552554 A5 JP2023552554 A5 JP 2023552554A5 JP 2023534111 A JP2023534111 A JP 2023534111A JP 2023534111 A JP2023534111 A JP 2023534111A JP 2023552554 A5 JP2023552554 A5 JP 2023552554A5
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
level
composition according
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552554A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062078 external-priority patent/WO2022120292A1/en
Publication of JP2023552554A publication Critical patent/JP2023552554A/ja
Publication of JP2023552554A5 publication Critical patent/JP2023552554A5/ja
Pending legal-status Critical Current

Links

JP2023534111A 2020-12-06 2021-12-06 フィツシランを用いた血友病の処置 Pending JP2023552554A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063121973P 2020-12-06 2020-12-06
US63/121,973 2020-12-06
US202163272629P 2021-10-27 2021-10-27
US63/272,629 2021-10-27
US202163275344P 2021-11-03 2021-11-03
US63/275,344 2021-11-03
PCT/US2021/062078 WO2022120292A1 (en) 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran

Publications (2)

Publication Number Publication Date
JP2023552554A JP2023552554A (ja) 2023-12-18
JP2023552554A5 true JP2023552554A5 (cg-RX-API-DMAC7.html) 2024-12-13

Family

ID=80112089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534111A Pending JP2023552554A (ja) 2020-12-06 2021-12-06 フィツシランを用いた血友病の処置

Country Status (10)

Country Link
US (1) US20240027478A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552554A (cg-RX-API-DMAC7.html)
KR (1) KR20230117403A (cg-RX-API-DMAC7.html)
AU (1) AU2021391951A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204344A1 (cg-RX-API-DMAC7.html)
IL (1) IL303452A (cg-RX-API-DMAC7.html)
MX (1) MX2023006651A (cg-RX-API-DMAC7.html)
TW (1) TW202237151A (cg-RX-API-DMAC7.html)
WO (1) WO2022120292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3258425A1 (en) * 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran in pediatric patients
EP4612687A1 (en) 2022-11-02 2025-09-10 Genzyme Corporation Systems and methods for modeling thrombin-antithrombin
TW202525306A (zh) * 2023-09-15 2025-07-01 美商健臻公司 用非妥西蘭(fitusiran)治療a型血友病
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) * 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物

Similar Documents

Publication Publication Date Title
Reasbeck et al. Double-blind controlled trial of indomethacin as an adjunct to narcotic analgesia after major abdominal surgery
US5145852A (en) Vaso-active medicament to treat impotence
Chaowagul et al. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis
CA2867343C (en) Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
KR102438597B1 (ko) 항종양제의 투여 방법
JP2018531605A5 (cg-RX-API-DMAC7.html)
JP2019501886A5 (cg-RX-API-DMAC7.html)
Fontana et al. Direct oral anticoagulants: a guide for daily practice
JP2008539273A5 (cg-RX-API-DMAC7.html)
JP2023552554A (ja) フィツシランを用いた血友病の処置
Songdej et al. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with β-thalassemia: 3-year experience
RU2007101686A (ru) Комбинированная композиция
Krivokuca et al. Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid.
Jerums et al. Long‐term renoprotection by perindopril or nifedipine in non‐hypertensive patients with type 2 diabetes and microalbuminuria
CN115052628A (zh) 抗pd-1抗体在治疗肿瘤中的用途
JP2021152002A5 (cg-RX-API-DMAC7.html)
JP6885649B2 (ja) 統合失調症の治療のためのイロペリドン
EP4536246A2 (en) Fitusiran for the treatment of hemophilia a and b in pediatric patients
Farkas et al. Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency.
CN116157119A (zh) 一种ARNi与钙离子拮抗剂的药物组合物与应用
Michot et al. A double-blind clinical trial to determine if an interaction exists between diclofenac sodium and the oral anticoagulant acenocoumarol (nicoumalone)
JP2019001830A (ja) 医薬
JP2008539265A5 (cg-RX-API-DMAC7.html)
Grothey Optimal use of Regorafenib: Dosing strategies and patient selection
Bliding Efficacy of antianxiety drug therapy in alcohol post-intoxication symptoms: a double-blind study of chlorprothixen, oxazepam and placebo